Abstract

The LDL lowering therapies have a major role in reduction in cardiovascular events. Statins have been shown to be highly effective and safe in numerous randomized clinical trials, and have become the irreplacablee first-line treatment against atherogenic dyslipidemia. However, even with optimal statin and other traditional treatment, there still remains 60% to 80% of residual cardiovascular risk. Monoclonal antibodies to proprotein convertasesubtilisin kexin type 9 (PCSK9) represent a new therapeutic option, reducing LDL cholesterol by an additional 40–70% on top of other lipid lowering therapies. Some more novel lipid- lowering therapies and HDL-raising interventions are emerging, however, they require large cardiovascular outcome trials. Clinicians should be aware of the results of outcome trials with novel drugs in treatment of atherogenic dyslipidaemia in order to offer the most efficacious and safe treatment to their patients.